Expression and prognostic significance of CIP2A in cutaneous malignant melanoma

Biomarkers

Volumn 19, Issue 1, 2014, Pages 70-76

  Shi, Feng ^a   Ding, Yayun ^a   Ju, Shaoqing ^a   Wu, Xinhua ^a   Cao, Shuanglin ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

CIP2A; CMM; Prognosis; Survival

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MATRIGEL; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOASSAY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CUTANEOUS MALIGNANT MELANOMA; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MATRIGEL INVASION ASSAY; MATRIGEL MIGRATION ASSAY; MELANOMA; METASTASIS; MIDDLE AGED; PROTEIN EXPRESSION; SCRATCH MIGRATION ASSAY; WESTERN BLOTTING;

AUTOANTIGENS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893269709     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.871752     Document Type: Article

References (27)

1. Balch CM, Gershenwald JE, Soong SJ, et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-206.
2. Basile JR, Czerninski R. (2010). The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther 10:700-2.
3. Bo?ckelman C, Hagstro?m J, Ma? kinen LK, et al. (2011). High CIP2A immunoreactivity is an independent prognostic indicator in earlystage tongue cancer. Br J Cancer 104:1890-5.
4. Chen KF, Liu CY, Lin YC, et al. (2010). CIP2A mediates effect of Bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29:6257-66.
5. Co?me C, Laine A, Chanrion M, et al. (2009). CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15:5092-100.
6. Dennis LK. (1999). Analysis of the melanoma epidemic, both apparent and real: Data from the 1973 through 1994 surve illance, epidemiology, and end results program registry. Arch Dermatol 135:275-80.
7. Dong QZ, Wang Y, Dong XJ, et al. (2011). CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18:857-65.
8. Fang Y, Li Z, Wang X, Zhang S . (2012). CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol 33:2299-306.
9. He H, Wu G, Li W, et al. (2012). CIP2A is highly expressed in hepatocel lular carcinoma and predicts poor prognosis. Diagn Mol Pathol 21:143-9.
10. Huang LP, Adelson ME, Mordechai E, Trama JP. (2011). CIP2A expression is elevated in cervical cancer. Cancer Biomark 8:309-17.
11. Huang P, Qiu J, You J, et al. (2012). Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 5:422-9.
12. Junttila MR, Puustinen P, Niemela M, et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130:51-62.
13. Junttila MR, Westermarch J. (2008). Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7:592-6.
14. Lee J, Park EJ, Hwang JW, et al. (2011). CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol Int 32:2023-30.
15. Li W, Ge Z, Liu C, et al. (2008). CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14:3722-8.
16. Lin YC, Chen KC, Chen CC, et al. (2012). CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinomacells. Oral Oncol 48:585-93.
17. Liu CY, Shiau CW, Kuo HY, et al. (2013). Cancerous inhibitor of protein phosphatese 2A determines Bortezomib-induced apoptosis in leukemia cells. Haematologica 98:729-38.
18. Ren J, Li W, Yan L, et al. (2011). Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients? survival. Br J Cancer 105:1905-11.
19. Seth A, Watson DK. (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462-78.
20. Seth A, Catzavelos C, Vary C, Ascione R. (2001). ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis. Expert Opin Ther Targets 5:87-107.
21. Seth A, Papas TS. (1990). The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. Oncogene 5:1761-7.
22. Simard EP, Ward EM, Siegel R, Jemal A. (2012). Cancers with increasing i ncidence trends in the United States: 1999 through 2008. CA Cancer J Clin 13:118-28.
23. Teng HW, Yang SH, Lin JK, et al. (2002). CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 16:1037-47.
24. Tseng LM, Liu CY, Chang KC, et al. (2012). CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 14:68-82.
25. Vaarala MH, Va?isa?nen MR, Ristima? ki A. (2010). CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29:136. doi: 10.1186/1756-9966-29-136.
26. Viola JR, Rafael DF, Wagner E, et al. (2013). Gene therapy for advanced melanoma: Selective targeting and therapeutic nucleic acids. J Drug Deliv. [Epub ahead of print]. doi: 10.1155/2013/897348.
27. Wang J, Li W, Li L, et al. (2011). CIP2A is overexpressed in acute myeloid leukemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 33:290-8.